<DOC>
	<DOCNO>NCT01858662</DOCNO>
	<brief_summary>To analyze pathological tumor response resect colorectal cancer metastasis preoperative treatment cetuximab combine FOLFOX FOLFIRI regimen prospective cohort ( RAS B-RAF WT tumor ) correlate response patient 's outcome .</brief_summary>
	<brief_title>Study Comparing Pathological Responses Observed Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX FOLFIRI RAS B-RAF WT Tumors</brief_title>
	<detailed_description>This phase II , openlabel , randomize study patient confirm diagnosis potentially borderline resectable metastatic colorectal adenocarcinoma ( RAS B-RAF WT tumor ) , receive prior chemotherapy metastatic disease . The study design compare pathological response observe pre-operative chemotherapy cetuximab FOLFOX FOLFIRI .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Female male patient least 18 year time inform consent sign 2 . ECOG performance status 0 1 3 . Histological cytological confirm diagnostic adenocarcinoma colon rectum , without primary tumour situ . Wildtype RAS BRAF tumor status . 4 . Patients potentially resectable metastatic disease diagnosis chemotherapy first curative intent recommend . Resectability could plan one multiple stage indicate . As commonly admit , resectability mean surgical clearance ( +/ radiofrequency ablation ) detectable ( liver ) lesion tumorfree margin compatible adequate hepatic reserve . Practically , bilateral tumor location , number location lesion , inadequate hepatic reserve remain main decisional factor . 5 . Partial minor resection metastatic disease allow within 3 month inclusion patient never receive chemotherapy mCRC . 6 . Extra hepatic metastatic location limit 1 site . 7 . Patients may receive adjuvant chemotherapy ( neo ) adjuvant chemoradiotherapy pelvis , provide last dose chemotherapy administer least 6 month prior inclusion ( 12 month oxaliplatin ) . Previous radiotherapy pelvis exclusion criterion . 8 . Adequate haematological , renal hepatic function follow : Haematological : haemoglobin &gt; 9g/dl Neutrophils &gt; 1.5 x 109/L Platelets &gt; 100 x 109/L Renal : Creatinine &lt; 1.5 x ULN ( Upper Limit Normal ) Hepatic : Bilirubin &lt; equal 1.5 X ULN AST ( Aspartate Aminotransferase ) , ALT ( Alanine Aminotransferase ) &lt; equal 5 x ULN , Phos Alc &lt; equal 5 x ULN 9 . Female patient must either postmenopausal , sterile ( surgically radiation chemicallyinduced ) , sexually active use acceptable method contraception . 10 . Male patient must surgically sterile sexually active premenopausal partner must use acceptable method contraception . 11 . Life expectancy least 3 month without active treatment . 1.Definitively non resectable mCRC diagnosis 2.Prior chemotherapy systemic therapy mCRC . Adjuvant chemotherapy colorectal cancer exclusion criterion provide complete 6 month prior inclusion . Oxaliplatinbased chemotherapy must complete 1 year prior inclusion . 3.Prior utilization cetuximab , panitumumab ( antiEGFR ( epidermal growth factor receptor ) therapy ) . 4.Previous radiotherapy deliver upper abdomen . 5 Non mesurable disease ( RECIST 1.1 criterion ) 6.Evidence ascites , cirrhosis , portal hypertension , main portal venous tumour involvement thrombosis determine clinical radiologic assessment . 7.Prior major liver resection : remnant liver &lt; 50 % initial liver volume . 8.Nonmalignant disease would render patient unsuitable treatment accord protocol . 9.Concurrent central nervous system metastases 10.Peripheric neuropathy â‰¥ grade 2 . 11.Interstitial lung disease 12.Pregnant breast feeding . 13.The patient previous concomitant malignancy , except : Invasive malignancy remission 5 year non melanoma skin cancer carcinoma situ cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>Liver</keyword>
	<keyword>cetuximab</keyword>
	<keyword>Pathological response</keyword>
</DOC>